You can buy or sell EIDX and other stocks, options, ETFs, and crypto commission-free!
Eidos Therapeutics, Inc. focuses on addressing the large and growing unmet need in diseases caused by transthyretin (TTR) amyloidosis (ATTR). Its product include the AG10, an orally-administered small molecule designed to potently stabilize TTR, suggesting a treatment with the potential to halt the progression of ATTR. Read More The company was founded by Graef Isabella and Alhamadsheh Mamoun on August 6, 2013 and is headquartered in San Francisco, CA.
San Francisco, California
52 Week High
52 Week Low
Associated PressApr 30
Research Report Identifies National General, Eidos Therapeutics, Auris Medical Holding AG, and Realogy with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
Press release content from Globe Newswire. The AP news staff was not involved in its creation. Press release content from Globe Newswire. The AP news staff was not involved in its creation. NEW YORK, April 30, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of National General Holdings Corp (NASDAQ:NGHC), Eidos Therapeutics, Inc. (NASDAQ:EIDX), Auris Medical H...
Expected Aug 6, After Hours